Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open-label, Phase IIb, Non-inferiority Proof of Principle Trial.

NCT03684564 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT03684564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03684564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open-label, Phase IIb, Non-inferiority Proof of Principle Trial.
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
July 9, 2021
Completion date
July 31, 2025
Enrollment
43 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome, brain ischemia, ischemic stroke, stroke, systemic lupus erythematosus